pAb; Rabbit anti Human Cathepsin L/MEP Antibody; WB, IHC; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab093200-10μl | 10μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $69.90 | |
| Ab093200-50μl | 50μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $189.90 | |
| Ab093200-100μl | 100μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $289.90 | |
| Ab093200-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,999.90 |
pAb; Rabbit anti Human Cathepsin L/MEP Antibody; WB, IHC; Unconjugated
| Product Name | Cathepsin L/MEP Antibody - Primary antibody, specific to Cathepsin L/MEP, Rabbit IgG |
|---|---|
| Synonyms | Cathepsin L1 | EC 3.4.22.15 | Major excreted protein | MEP | Cathepsin L antibody | cathepsin L, 1 b antibody | Cathepsin L1 antibody | Cathepsin L1 light chain antibody | CathepsinL antibody | CATL antibody | CATL1_HUMAN antibody | cb15 antibody | CTSL a |
| Specifications & Purity | ExactAb™, Validated, 1.0 mg/mL |
| Host species | Rabbit |
| Specificity | Cathepsin L/MEP |
| Immunogen | A synthetic peptide derived from the Internal region of human Cathepsin L. |
| Positive Control | WB: K562, HEK293 and A549 cell lysates. IHC: Human colon, liver tissues. |
| Conjugation | Unconjugated |
| Grade | ExactAb™, Validated |
| Product Description | Rabbit anti Human Cathepsin L/MEP Antibody, Polyclonal, could be used for WB, IHC and so on. |
| Isotype | Rabbit IgG |
|---|---|
| SDS-PAGE | 150 kDa |
| Purification Method | Immunogen affinity purified |
| Form | Liquid |
| Concentration | 1.0 mg/mL |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -20℃ long term (12 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
Cathepsin L/MEP Antibody (Ab093200) - Western Blot
All lanes: Cathepsin L/MEP Antibody (Ab093200) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 37 kDa
Observed band size: 38 kDa
Exposure time: 0.7 s
Cathepsin L/MEP Antibody (Ab093200) - IHC
Immunohistochemical analysis of paraffin-embedded human-colon, Cathepsin L/MEP Antibody (Ab093200) was diluted at 1/100
Cathepsin L/MEP Antibody (Ab093200) - IHC
Immunohistochemical analysis of paraffin-embedded human-liver, Cathepsin L/MEP Antibody (Ab093200) was diluted at 1/100
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Application | Dilution info |
|---|---|
| WB | 1/500-1/2000 |
| IHC | 1/100-1/300 |
Enter Lot Number to search for COA:
| 1. Mott BT, Ferreira RS, Simeonov A, Jadhav A, Ang KK, Leister W, Shen M, Silveira JT, Doyle PS, Arkin MR et al.. (2010) Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.. J Med Chem, 53 (1): (52-60). [PMID:19908842] |
| 2. Méthot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy TJ, Riendeau D, Percival MD. (2007) Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.. J Biol Chem, 282 (29): (20836-46). [PMID:17535802] |
| 3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al.. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.. Cell, 181 (2): (271-280.e8). [PMID:32142651] |
| 4. Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA. (2010) Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.. Biochimie, 92 (11): (1618-24). [PMID:20447439] |
| 5. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.. Proc Natl Acad Sci USA, 102 (33): (11876-81). [PMID:16081529] |
| 6. Izidor Sosič,Bojana Mirković,Katharina Arenz,Bogdan Stefane,Janko Kos,Stanislav Gobec. (2012-12-21) Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.. Journal of medicinal chemistry, 56 ((2)): (521-533). [PMID:23252745] |
| 7. Xiao-Yu Yuan,Zhongyuan Ren,Yuqing Wu,Carole Bougault,Leyre Brizuela,David Magne,René Buchet,Saida Mebarek. (2019-02-19) Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.. Bioorganic & medicinal chemistry, 27 ((6)): (1034-1042). [PMID:30773420] |
| 8. Mendonca RV, Venkatraman S, Palmer JT.. (2002) Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors.. Bioorg Med Chem Lett, 12 (20): (2887-2891). [PMID:12270170] |
| 9. Greenspan PD, Clark KL, Tommasi RA, Cowen SD, McQuire LW, Farley DL, van Duzer JH, Goldberg RL, Zhou H, Du Z, Fitt JJ, Coppa DE, Fang Z, Macchia W, Zhu L, Capparelli MP, Goldstein R, Wigg AM, Doughty JR, Bohacek RS, Knap AK.. (2001) Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.. J Med Chem, 44 (26): (4524-4534). [PMID:11741472] |
| 10. Marquis RW, Ru Y, Zeng J, Trout RE, LoCastro SM, Gribble AD, Witherington J, Fenwick AE, Garnier B, Tomaszek T, Tew D, Hemling ME, Quinn CJ, Smith WW, Zhao B, McQueney MS, Janson CA, D'Alessio K, Veber DF.. (2001) Cyclic ketone inhibitors of the cysteine protease cathepsin K.. J Med Chem, 44 (5): (725-736). [PMID:11262083] |
| 11. Huang L, Lee A, Ellman JA.. (2002) Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis.. J Med Chem, 45 (3): (676-684). [PMID:11806719] |
| 12. Robichaud J, Oballa R, Prasit P, Falgueyret JP, Percival MD, Wesolowski G, Rodan SB, Kimmel D, Johnson C, Bryant C, Venkatraman S, Setti E, Mendonca R, Palmer JT.. (2003) A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.. J Med Chem, 46 (17): (3709-3727). [PMID:12904076] |
| 13. Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Wells-Knecht KJ, Wright LL.. (2005) A structural screening approach to ketoamide-based inhibitors of cathepsin K.. Bioorg Med Chem Lett, 15 (9): (2209-2213). [PMID:15837295] |
| 14. Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, Venkatraman S, Tian ZQ, Burrill LC, Mendonca RV, Springman E, McCarter J, Chung T, Cheung H, Janc JW, McGrath M, Somoza JR, Enriquez P, Yu ZW, Strickley RM, Liu L, Venuti MC, Percival MD, Falgueyret JP, Prasit P, Oballa R, Riendeau D, Young RN, Wesolowski G, Rodan SB, Johnson C, Kimmel DB, Rodan G.. (2005) Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.. J Med Chem, 48 (24): (7520-7534). [PMID:16302794] |
| 15. Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Massé F, Riendeau D, Toulmond S, Percival MD.. (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.. J Med Chem, 48 (24): (7535-7543). [PMID:16302795] |
| 16. Martina E, Stiefl N, Degel B, Schulz F, Breuning A, Schiller M, Vicik R, Baumann K, Ziebuhr J, Schirmeister T.. (2005) Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.. Bioorg Med Chem Lett, 15 (24): (5365-5369). [PMID:16216498] |
| 17. Palmer JT, Hirschbein BL, Cheung H, McCarter J, Janc JW, Yu ZW, Wesolowski G.. (2006) Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.. Bioorg Med Chem Lett, 16 (11): (2909-2914). [PMID:16546382] |
| 18. Setti EL, Venkatraman S, Palmer JT, Xie X, Cheung H, Yu W, Wesolowski G, Robichaud J.. (2006) Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.. Bioorg Med Chem Lett, 16 (16): (4296-4299). [PMID:16750630] |
| 19. Mallari JP, Shelat AA, Obrien T, Caffrey CR, Kosinski A, Connelly M, Harbut M, Greenbaum D, McKerrow JH, Guy RK.. (2008) Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.. J Med Chem, 51 (3): (545-552). [PMID:18173229] |
| 20. Irie O, Kosaka T, Kishida M, Sakaki J, Masuya K, Konishi K, Yokokawa F, Ehara T, Iwasaki A, Iwaki Y, Hitomi Y, Toyao A, Gunji H, Teno N, Iwasaki G, Hirao H, Kanazawa T, Tanabe K, Hiestand PC, Malcangio M, Fox AJ, Bevan SJ, Yaqoob M, Culshaw AJ, Hart TW, Hallett A.. (2008) Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.. Bioorg Med Chem Lett, 18 (19): (5280-5284). [PMID:18783943] |
| 21. Mallari JP, Shelat AA, Kosinski A, Caffrey CR, Connelly M, Zhu F, McKerrow JH, Guy RK.. (2009) Structure-guided development of selective TbcatB inhibitors.. J Med Chem, 52 (20): (6489-6493). [PMID:19769357] |
| 22. Kishore Kumar GD, Chavarria GE, Charlton-Sevcik AK, Arispe WM, Macdonough MT, Strecker TE, Chen SE, Siim BG, Chaplin DJ, Trawick ML, Pinney KG.. (2010) Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.. Bioorg Med Chem Lett, 20 (4): (1415-1419). [PMID:20089402] |
| 23. Rankovic Z, Cai J, Kerr J, Fradera X, Robinson J, Mistry A, Hamilton E, McGarry G, Andrews F, Caulfield W, Cumming I, Dempster M, Waller J, Scullion P, Martin I, Mitchell A, Long C, Baugh M, Westwood P, Kinghorn E, Bruin J, Hamilton W, Uitdehaag J, van Zeeland M, Potin D, Saniere L, Fouquet A, Chevallier F, Deronzier H, Dorleans C, Nicolai E.. (2010) Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.. Bioorg Med Chem Lett, 20 (5): (1524-1527). [PMID:20149657] |
| 24. Rankovic Z, Cai J, Fradera X, Dempster M, Mistry A, Mitchell A, Long C, Hamilton E, King A, Boucharens S, Jamieson C, Gillespie J, Cumming I, Uitdehaag J, van Zeeland M.. (2010) Dioxo-triazines as a novel series of cathepsin K inhibitors.. Bioorg Med Chem Lett, 20 (5): (1488-1490). [PMID:20153187] |
| 25. Dossetter AG, Beeley H, Bowyer J, Cook CR, Crawford JJ, Finlayson JE, Heron NM, Heyes C, Highton AJ, Hudson JA, Jestel A, Kenny PW, Krapp S, Martin S, MacFaul PA, McGuire TM, Gutierrez PM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C, Vickers M.. (2012) (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.. J Med Chem, 55 (14): (6363-6374). [PMID:22742641] |
| 26. Song J, Jones LM, Chavarria GE, Charlton-Sevcik AK, Jantz A, Johansen A, Bayeh L, Soeung V, Snyder LK, Lade SD, Chaplin DJ, Trawick ML, Pinney KG.. (2013) Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.. Bioorg Med Chem Lett, 23 (9): (2801-2807). [PMID:23540644] |
| 27. Miller B, Friedman AJ, Choi H, Hogan J, McCammon JA, Hook V, Gerwick WH.. (2014) The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L.. J Nat Prod, 77 (1): (92-99). [PMID:24364476] |
| 28. Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D.. (2014) Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.. J Med Chem, 57 (22): (9598-9611). [PMID:25330343] |
| 29. Burger MC, Fernandes JB, da Silva MF, Escalante A, Prudhomme J, Le Roch KG, Izidoro MA, Vieira PC.. (2014) Structures and bioactivities of dihydrochalcones from Metrodorea stipularis.. J Nat Prod, 77 (11): (2418-2422). [PMID:25375026] |
| 30. Borišek J, Vizovišek M, Sosnowski P, Turk B, Turk D, Mohar B, Novič M.. (2015) Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.. J Med Chem, 58 (17): (6928-6937). [PMID:26280490] |
| 31. Parker EN, Song J, Kishore Kumar GD, Odutola SO, Chavarria GE, Charlton-Sevcik AK, Strecker TE, Barnes AL, Sudhan DR, Wittenborn TR, Siemann DW, Horsman MR, Chaplin DJ, Trawick ML, Pinney KG.. (2015) Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.. Bioorg Med Chem, 23 (21): (6974-6992). [PMID:26462052] |
| 32. Choi JY, Fuerst R, Knapinska AM, Taylor AB, Smith L, Cao X, Hart PJ, Fields GB, Roush WR.. (2017) Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.. J Med Chem, 60 (13): (5816-5825). [PMID:28653849] |
| 33. Giroud M, Dietzel U, Anselm L, Banner D, Kuglstatter A, Benz J, Blanc JB, Gaufreteau D, Liu H, Lin X, Stich A, Kuhn B, Schuler F, Kaiser M, Brun R, Schirmeister T, Kisker C, Diederich F, Haap W.. (2018) Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors.. J Med Chem, 61 (8): (3350-3369). [PMID:29590750] |
| 34. Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.. (2018) 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.. J Med Chem, 61 (8): (3370-3388). [PMID:29590751] |
| 35. Capuzzi SJ, Sun W, Muratov EN, Martínez-Romero C, He S, Zhu W, Li H, Tawa G, Fisher EG, Xu M, Shinn P, Qiu X, García-Sastre A, Zheng W, Tropsha A.. (2018) Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.. J Med Chem, 61 (8): (3582-3594). [PMID:29624387] |
| 36. Zwicker JD, Diaz NA, Guerra AJ, Kirchhoff PD, Wen B, Sun D, Carruthers VB, Larsen SD.. (2018) Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.. Bioorg Med Chem Lett, 28 (10): (1972-1980). [PMID:29650289] |
| 37. Sosič I, Mitrović A, Ćurić H, Knez D, Brodnik Žugelj H, Štefane B, Kos J, Gobec S.. (2018) Cathepsin B inhibitors: Further exploration of the nitroxoline core.. Bioorg Med Chem Lett, 28 (7): (1239-1247). [PMID:29503024] |
| 38. Zhang H, Collins J, Nyamwihura R, Ware S, Kaiser M, Ogungbe IV.. (2018) Discovery of a quinoline-based phenyl sulfone derivative as an antitrypanosomal agent.. Bioorg Med Chem Lett, 28 (9): (1647-1651). [PMID:29609908] |
| 39. Galibert M, Wartenberg M, Lecaille F, Saidi A, Mavel S, Joulin-Giet A, Korkmaz B, Brömme D, Aucagne V, Delmas AF, Lalmanach G.. (2018) Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.. Eur J Med Chem, 144 (201-210). [PMID:29272750] |
| 40. Chowdhury SR, Kennedy S, Zhu K, Mishra R, Chuong P, Nguyen AU, Kathman SG, Statsyuk AV.. (2019) Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.. Bioorg Med Chem Lett, 29 (1): (36-39). [PMID:30455147] |
| 41. Boudreau PD, Miller BW, McCall LI, Almaliti J, Reher R, Hirata K, Le T, Siqueira-Neto JL, Hook V, Gerwick WH.. (2019) Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain.. J Med Chem, 62 (20): (9026-9044). [PMID:31539239] |
| 42. Hou W, Sun H, Ma Y, Liu C, Zhang Z.. (2019) Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.. J Med Chem, 62 (12): (5901-5919). [PMID:31145622] |
| 43. Fonović UP,Knez D,Hrast M,Zidar N,Proj M,Gobec S,Kos J. (2020) Structure-activity relationships of triazole-benzodioxine inhibitors of cathepsin X.. Eur J Med Chem, 193 (112218-112218). [PMID:32208223] |
| 44. Ribeiro JFR,Cianni L,Li C,Warwick TG,de Vita D,Rosini F,Dos Reis Rocho F,Martins FCP,Kenny PW,Lameira J,Leitão A,Emsley J,Montanari CA. (2020) Crystal structure of Leishmania mexicana cysteine protease B in complex with a high-affinity azadipeptide nitrile inhibitor.. Bioorg Med Chem, 28 (22): (115743-115743). [PMID:33038787] |
| 45. Quancard J,Simic O,Pissot Soldermann C,Aichholz R,Blatter M,Renatus M,Erbel P,Melkko S,Endres R,Sorge M,Kieffer L,Wagner T,Beltz K,Mcsheehy P,Wartmann M,Régnier CH,Calzascia T,Radimerski T,Bigaud M,Weiss A,Bornancin F,Schlapbach A. (2020) Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.. J Med Chem, 63 (23): (14594-14608). [PMID:33216547] |
| 46. Joseph, L J LJ, Chang, L C LC, Stamenkovich, D D and Sukhatme, V P VP.. (1988) Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts.. The Journal of clinical investigation, [PMID:2835398] |
| 47. Ritonja, A A, Popović, T T, Kotnik, M M, Machleidt, W W and Turk, V V.. (1988) Amino acid sequences of the human kidney cathepsins H and L.. FEBS letters, (15): [PMID:3342889] |
| 48. Gal, S S and Gottesman, M M MM.. (1988) Isolation and sequence of a cDNA for human pro-(cathepsin L).. The Biochemical journal, (1): [PMID:3421948] |
| 49. Mason, R W RW, Walker, J E JE and Northrop, F D FD.. (1986) The N-terminal amino acid sequences of the heavy and light chains of human cathepsin L. Relationship to a cDNA clone for a major cysteine proteinase from a mouse macrophage cell line.. The Biochemical journal, (1): [PMID:3545185] |
| 50. Joseph, L L, Lapid, S S and Sukhatme, V V.. (1987) The major ras induced protein in NIH3T3 cells is cathepsin L.. Nucleic acids research, (10): [PMID:3550705] |
| 51. Coulombe, R R and 5 more authors.. (1996) Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment.. The EMBO journal, (15): [PMID:8896443] |
| 52. Fujishima, A A and 5 more authors.. (1997) The crystal structure of human cathepsin L complexed with E-64.. FEBS letters, (21): [PMID:9141479] |
| 53. Ménard, R R and 6 more authors.. (1998) Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro.. The Journal of biological chemistry, (20): [PMID:9468501] |
| 54. Felbor, U U and 5 more authors.. (2000) Secreted cathepsin L generates endostatin from collagen XVIII.. The EMBO journal, (15): [PMID:10716919] |
| 55. Zhang, Hui H, Li, Xiao-Jun XJ, Martin, Daniel B DB and Aebersold, Ruedi R.. (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.. Nature biotechnology, [PMID:12754519] |
| 56. Goulet, Brigitte B and 7 more authors.. (2004) A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor.. Molecular cell, (23): [PMID:15099520] |
| 57. Humphray, S J SJ and 147 more authors.. (2004) DNA sequence and analysis of human chromosome 9.. Nature, (27): [PMID:15164053] |
| 58. Liu, Tao T and 6 more authors.. () Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952] |
| 59. Bechtel, Stephanie S and 18 more authors.. (2007) The full-ORF clone resource of the German cDNA Consortium.. BMC genomics, (31): [PMID:17974005] |
| 60. Rosenow, Anja A and 6 more authors.. (2012) Resveratrol-induced changes of the human adipocyte secretion profile.. Journal of proteome research, (7): [PMID:22905912] |
| 61. Bian, Yangyang Y and 9 more authors.. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.. Journal of proteomics, (16): [PMID:24275569] |
| 62. Zhou, Nan N and 11 more authors.. (2016) Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).. The Journal of biological chemistry, (22): [PMID:26953343] |
| 63. van den Bogaard, Ellen H J EHJ and 11 more authors.. (2019) Deficiency of the human cysteine protease inhibitor cystatin M/E causes hypotrichosis and dry skin.. Genetics in medicine : official journal of the American College of Medical Genetics, [PMID:30425301] |
| 64. Ou, Xiuyuan and 17 more authors.. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.. Nature communications, (27): [PMID:32221306] |
| 65. Smieszek, Sandra P; Przychodzen, Bart P and Polymeropoulos, Mihael H.. (2020) Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment.. International journal of antimicrobial agents, [PMID:32361028] |
| 66. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge. (2011-01-29) Initial characterization of the human central proteome.. BMC systems biology, 5 (17-17). [PMID:21269460] |
